Benign Prostatic Hyperplasia (BPH) is one of the most common urological conditions affecting aging men, often causing urinary frequency, urgency, weak urine flow, and incomplete bladder emptying. As healthcare providers increasingly adopt transurethral resection of the prostate, laser prostate surgery, and minimally invasive BPH treatment, patients now have access to safer procedures with faster recovery times and improved quality of life. These advancements are also driving growth in the U.S. Benign Prostatic Hyperplasia Surgical Treatment Market, supported by technological innovation, an aging population, and growing awareness of effective surgical options.

The U.S. Benign Prostatic Hyperplasia Surgical Treatment Market is projected to grow at a CAGR of 5.6% from 2025 to 2034, increasing from USD 753.66 million in 2025 to USD 1,232.65 million by 2034.

Understanding Benign Prostatic Hyperplasia

Benign Prostatic Hyperplasia is a non-cancerous enlargement of the prostate gland that commonly develops with age. As the prostate enlarges, it compresses the urethra, restricting urine flow and causing lower urinary tract symptoms (LUTS). While medications provide relief for many patients, surgery becomes necessary when symptoms become severe or complications such as urinary retention occur.

The evolution of surgical technology has shifted treatment away from traditional invasive procedures toward minimally invasive techniques that reduce hospital stays, minimize complications, and improve patient satisfaction.

Transurethral Resection of the Prostate Remains the Gold Standard

Among all surgical procedures, transurethral resection of the prostate (TURP) continues to be regarded as the benchmark treatment for moderate to severe BPH. During the procedure, surgeons insert a specialized instrument through the urethra to remove excess prostate tissue, restoring normal urinary flow without external incisions.

TURP offers several important benefits:

• Significant improvement in urinary symptoms
• Long-term clinical effectiveness
• High success rate for moderate and severe BPH
• Extensive clinical evidence supporting safety and efficacy

According to Polaris Market Research, the TURP segment accounted for the largest share of the U.S. Benign Prostatic Hyperplasia Surgical Treatment Market in 2024 because of its proven effectiveness and established clinical adoption.

Laser Prostate Surgery Offers Faster Recovery

Technological innovation has led to the widespread adoption of laser prostate surgery, providing patients with an effective alternative to conventional surgery.

Laser procedures use concentrated laser energy to remove or vaporize enlarged prostate tissue while minimizing bleeding and preserving surrounding structures. Common laser techniques include laser vaporization and laser enucleation, both designed to relieve urinary obstruction with reduced postoperative complications.

Key advantages include:

• Reduced blood loss
• Shorter hospitalization
• Faster recovery
• Lower risk of complications
• Suitable for patients taking blood-thinning medications

As hospitals continue investing in advanced surgical platforms, laser procedures are becoming an increasingly preferred option for both physicians and patients seeking minimally invasive care.

Growth of Minimally Invasive BPH Treatment

The healthcare industry is witnessing rapid adoption of minimally invasive BPH treatment options that provide symptom relief without extensive surgery.

Modern therapies now include:

• Prostatic urethral lift
• Water vapor therapy
• Aquablation therapy
• Laser therapy
• Transurethral microwave thermotherapy (TUMT)

These procedures generally require shorter operating times, enable same-day discharge, reduce postoperative discomfort, and allow patients to resume normal activities more quickly than traditional surgery.

The increasing preference for outpatient care is encouraging hospitals and ambulatory surgery centers to expand their minimally invasive treatment offerings, contributing to sustained market growth.

Technological Innovations Are Driving Market Expansion

Advanced surgical technologies continue to reshape BPH treatment across the United States. Robotic-assisted systems, AI-enabled surgical planning, precision imaging, and improved visualization tools are enhancing procedural accuracy while improving patient outcomes.

Recent product innovations include robotic aquablation systems and upgraded minimally invasive treatment platforms that enable surgeons to treat a wider range of prostate anatomies with greater precision. These innovations are strengthening physician confidence while encouraging broader adoption of surgical intervention for BPH.

Discover the Complete Report Here:

https://www.polarismarketresearch.com/industry-analysis/us-benign-prostatic-hyperplasia-surgical-treatment-market

Key Players

• Boston Scientific Corporation
• Cleveland Clinic
• Cook Medical
• Eli Lilly and Company
• Medifocus, Inc.
• Medtronic
• PROCEPT BioRobotics Corporation
• Teleflex Incorporated
• The Johns Hopkins Hospital
• Viatris Inc.

Growing Opportunities in the U.S. Benign Prostatic Hyperplasia Surgical Treatment Market

The U.S. Benign Prostatic Hyperplasia Surgical Treatment Market continues to expand due to several important factors:

• Rapid growth of the aging male population
• Increasing prevalence of lower urinary tract symptoms
• Rising awareness regarding early diagnosis and treatment
• Greater demand for minimally invasive surgical procedures
• Continuous innovation in urology devices
• Expansion of ambulatory surgery centers

Hospitals currently represent the largest end-user segment, while ambulatory surgery centers are expected to record the fastest growth during the forecast period as more BPH procedures shift to outpatient settings.

Future Outlook

The future of BPH surgical treatment is expected to focus on personalized care, robotic assistance, AI-guided procedures, and increasingly minimally invasive techniques. As healthcare providers continue adopting innovative technologies, patients will benefit from improved precision, reduced recovery times, and better long-term outcomes.

With transurethral resection of the prostate maintaining its clinical leadership, laser prostate surgery expanding rapidly, and minimally invasive BPH treatment becoming the preferred option for many patients, the U.S. Benign Prostatic Hyperplasia Surgical Treatment Market is well positioned for sustained growth over the next decade.

More Trending Latest Reports By Polaris Market Research:

Covid-19 Diagnostics Market

Molecular Cytogenetics Market

Endoscopic Submucosal Dissection Market

Catheters Market

Neovagina Surgery Market

Human Growth Hormone Market

U.S. AAMI Level 3 Surgical Gown Market

Anti-pollution Nasal Spray Market